While prior authorizations are put in place to ensure appropriate use of expensive therapies, they create a substantial burden for clinicians and patients, said Sabin Dang, MD, ophthalmologist with The Retina Institute.
While prior authorizations are put in place to ensure appropriate use of expensive therapies, they create a substantial burden for clinicians and patients, said Sabin Dang, MD, ophthalmologist with The Retina Institute.
Transcript
Prior authorization (PA) is supposed to ensure appropriate use of expensive therapies, such as anti-VEGF, but what additional cost and team burdens are PAs putting on practices?
So, prior authorization in ophthalmology, and broadly in medicine, has created additional barriers for us, as clinicians, to provide care to our patients. We do understand that, you know, these therapeutics do have a high cost associated with them, so there is a system needed to be put into place to monitor appropriate use of those medications.
What we find in our field is that these prior authorizations are creating a substantial burden for clinicians and patients. Specifically, the amount of administrative time a staff is required to spend in order to secure those prior authorizations has become very substantial. But additionally, patient's care may be delayed by going through that process. So, we could have a patient who comes in, the physician has identified treatment is needed, they go through the prior authorization process, and instead of the patient being able to get same-day treatment, they instead have to take another day off work, ask the relatives again for another ride so that they can come back to the office to get a treatment that the physician had already thought was necessary.
The combination of those 2 things are creating fewer available appointments for us to care for other patients, but additionally incurring a substantial amount of administrative cost and time in order to provide appropriate treatment.
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Prevention, Early Intervention Highlighted in Updated High Blood Pressure Guidelines
September 4th 2025A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Prevention, Early Intervention Highlighted in Updated High Blood Pressure Guidelines
September 4th 2025A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.
Read More
2 Commerce Drive
Cranbury, NJ 08512